{"title":"Zanamivir","summary":"Zanamivir is a medication used to treat and prevent influenza caused by influenza A and B viruses. It is a neuraminidase inhibitor and was developed by the Australian biotech firm Biota Holdings. It was licensed to Glaxo in 1990 and approved in the US in 1999, only for use as a treatment for influenza. In 2006, it was approved for prevention of influenza A and B.[1]  Zanamivir was the first neuraminidase inhibitor commercially developed. It is currently marketed by GlaxoSmithKline under the trade name Relenza as a powder for oral inhalation.","image":"Zanamivir_structure.svg.png.webp","url":"Zanamivir"}